Literature DB >> 3922650

Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance.

J Bernadou, J P Armand, A Lopez, M C Malet-Martino, R Martino.   

Abstract

We determined the urinary excretion of 5-fluorouracil (5FU) and its metabolites during six days of chemotherapy, using the non-invasive approach of 19F nuclear magnetic resonance. With this method, which requires no labeled drug, one can study the biological sample directly and simultaneously identify and quantify all the fluorinated metabolites. The daily urinary excretion of 5FU and its metabolites was high (94.8% of 5FU administered) and nearly constant all during the treatment. By far the major excreted catabolite was alpha-fluoro-beta-alanine, which made up 78.9% of the total. Unchanged 5FU (10.8% of dose injected) was found only during the first 2 h after injection. We observed neither accumulation of 5FU nor modifications in its metabolism during the treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922650

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Uses and limitations of nuclear magnetic resonance (NMR) spectroscopy in clinical pharmacokinetics.

Authors:  M C Malet-Martino; R Martino
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.

Authors:  M C Malet-Martino; P Servin; J Bernadou; J P Armand; R Martino
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

Review 4.  How may anticancer chemotherapy with fluorouracil be individualised?

Authors:  Su-arpa Ploylearmsaeng; Uwe Fuhr; Alexander Jetter
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 5.  Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer.

Authors:  P Chrisp; D McTavish
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

6.  Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.

Authors:  W Wolf; C A Presant; K L Servis; A el-Tahtawy; M J Albright; P B Barker; R Ring; D Atkinson; R Ong; M King
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

7.  Locoregional administration of 5-fluoro-2'-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy.

Authors:  B Naser-Hijazi; M R Berger; D Schmähl; P Schlag; W E Hull
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 8.  Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.

Authors:  Nattawut Leelakanok; Sean Geary; Aliasger Salem
Journal:  J Pharm Sci       Date:  2017-10-16       Impact factor: 3.784

9.  5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.

Authors:  M Arellano; M Malet-Martino; R Martino; T Spector
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.